Ursodeoxycholic acid in complex treatment of metabolic syndrome

Abstract

Aim of investigation. Evaluation of effect of ursodeoxycholic acid (Ursosan) on levels of immunoreactive insulin, leptin, clinical and biochemical tests in metabolic syndrome.Material and methods. The group of patients with metabolic syndrome (66 patients, aged 38 to 67 years) received Ursosan within complex treatment. Control group included 21 patients. Dynamics of immunoreactive insulin, leptin, lipid spectrum was determined by immunoenzyme test.Results. Significant decrease of transaminase, gamma-glutamyltranspeptidase, alkaline phosphatase activity, total cholesterol, triglyceride level, atherogenicity index was found in patients receiving Ursosan 15 mg/kg of body weight for 8 wks within complex treatment with trend for decrease of leptin and hyperinsulinemia level.Conclusions. Addition of Ursosan to complex treatment of patients with metabolic syndrome results in significant decrease of immunoreactive insulin, atherogenous fractions of lipids parameters with the tendency for decrease of leptin that playing the leading role in development and progression of metabolic syndrome.

Keywords

• metabolic syndrome
• ursosan
• immunoreactive insulin
• leptin
• gamma-glutamyltranspeptidase
• triglycerides